In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates

Transfusion

Volumn 55, Issue 9, 2015, Pages 2219-2230

  Abonnenc, Mélanie ^a   Sonego, Giona ^a   Crettaz, David ^a   Aliotta, Alessandro ^a   Prudent, Michel ^a   Tissot, Jean Daniel ^a   Lion, Niels ^a  

^a Transfusion Interrégionale CRS Laboratoire de Recherche sur les Produits Sanguins   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRINOGEN; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; DUSP2 PROTEIN, HUMAN; FUROCOUMARIN DERIVATIVE; PADGEM PROTEIN; SELP PROTEIN, HUMAN;

ANAEROBIC GLYCOLYSIS; ARTICLE; BLOOD GAS ANALYSIS; CELL ADHESION; FLOW CYTOMETRY; HUMAN; ILLUMINATION; IN VITRO STUDY; METABOLITE; MITOCHONDRION; PROTEIN EXPRESSION; RADIATION INJURY; SHOCK; STORAGE; THROMBOCYTE FUNCTION; ULTRAVIOLET B RADIATION; BLOOD; BLOOD BUFFY COAT; BLOOD CLOTTING PARAMETERS; BLOOD STORAGE; DRUG EFFECTS; FEMALE; GLYCOLYSIS; MALE; METABOLISM; OSMOTIC PRESSURE; PATHOLOGY; RADIATION RESPONSE; THROMBOCYTE; TIME; ULTRAVIOLET RADIATION;

ANNEXIN A5; BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD PRESERVATION; DUAL SPECIFICITY PHOSPHATASE 2; FEMALE; FLOW CYTOMETRY; FUROCOUMARINS; GLYCOLYSIS; HUMANS; MALE; OSMOTIC PRESSURE; P-SELECTIN; PLATELET FUNCTION TESTS; RIBOFLAVIN; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 84941803046     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13123     Document Type: Article

References (87)

1. Alter HJ, Klein HG,. The hazards of blood transfusion in historical perspective. Blood 2008; 112: 2617-26.
2. Vamvakas EC, Blajchman MA,. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24: 77-124.
3. Lai C, Cao H, Hearst JE, et al., Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. Anal Chem 2008; 80: 8790-8.
4. Cao H, Hearst JE, Corash L, et al., LC-MS/MS for the detection of DNA interstrand cross-links formed by 8-methoxypsoralen and UVA irradiation in human cells. Anal Chem 2008; 80: 2932-8.
5. Caffieri S,. Furocoumarin photolysis: chemical and biological aspects. Photochem Photobiol Sci 2002; 1: 149-57.
6. Cardoso DR, Libardi SH, Skibsted LH,. Riboflavin as a photosensitizer. Effects on human health and food quality. Food Funct 2012; 3: 487-502.
7. Lin L, Cook DN, Wiesehahn GP, et al., Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423-35.
8. Knutson F, Alfonso R, Dupuis K, et al., Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000; 78: 209-16.
9. Lin L, Hanson CV, Alter HJ, et al., Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45: 580-90.
10. Pinna D, Sampson-Johannes A, Clementi M, et al., Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med 2005; 15: 269-76.
11. Jauvin V, Alfonso RD, Guillemain B, et al., In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen. Transfusion 2005; 45: 1151-9.
12. Sawyer L, Hanson D, Castro G, et al., Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination. Transfusion 2007; 47: 1062-70.
13. Lin L, Dikeman R, Molini B, et al., Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496-504.
14. Brecher ME, Hay S, Corash L, et al., Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment. Transfusion 2007; 47: 1896-901.
15. Van Voorhis WC, Barrett LK, Eastman RT, et al., Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 2003; 47: 475-9.
16. Castro E, Gironés N, Bueno JL, et al., The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets. Transfusion 2007; 47: 434-41.
17. Grellier P, Benach J, Labaied M, et al., Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008; 48: 1676-84.
18. Eastman RT, Barrett LK, Dupuis K, et al., Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. Transfusion 2005; 45: 1459-63.
19. Grass JA, Hei DJ, Metchette K, et al., Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91: 2180-8.
20. Irsch J, Lin L,. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011; 38: 19-31.
21. Ruane PH, Edrich R, Gampp D, et al., Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
22. Goodrich RP, Gilmour D, Hovenga N, et al., A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-16.
23. Kaiser-Guignard J, Canellini G, Lion N, et al., The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014; 28: 235-41.
24. Janetzko K, Cazenave JP, Klüter H, et al., Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-52.
25. Lozano M, Knutson F, Tardivel R, et al., A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153: 393-401.
26. van Rhenen D, Gulliksson H, Cazenave JP, et al., Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
27. Infanti L, Stebler C, Job S, et al., Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study. Transfus Apher Sci 2011; 45: 175-81.
28. Corash L, Sherman CD., Evaluation of platelet transfusion clinical trials. Br J Haematol 2011; 153: 529-31; author reply 531-2.
29. Kerkhoffs JL, van Putten WL, Novotny VM, et al., Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
30. Sigle JP, Infanti L, Studt JD, et al., Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion 2013; 53: 1788-97.
31. Osselaer JC, Cazenave JP, Lambermont M, et al., An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-23.
32. Osselaer JC, Doyen C, Defoin L, et al., Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49: 1412-22.
33. Cazenave JP, Isola H, Waller C, et al., Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
34. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
35. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al., In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47: 653-65.
36. Picker SM, Speer R, Gathof BS,. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004; 44: 320-9.
37. van Rhenen DJ, Vermeij J, Mayaudon V, et al., Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79: 206-14.
38. Jansen GA, van Vliet HH, Vermeij H, et al., Functional characteristics of photochemically treated platelets. Transfusion 2004; 44: 313-9.
39. Hechler B, Ohlmann P, Chafey P, et al., Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 53: 1187-200.
40. Lozano M, Galan A, Mazzara R, et al., Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47: 666-71.
41. Abonnenc M, Sonego G, Kaiser J, et al., In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: the psoralen-based photochemical treatment step-by-step. Blood Transfus 2014; 23: 1-10.
42. AuBuchon JP, Herschel L, Roger J, et al., Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
43. Perez-Pujol S, Tonda R, Lozano M, et al., Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-9.
44. Picker SM, Steisel A, Gathof BS,. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40: 79-85.
45. Johnson L, Winter KM, Reid S, et al., The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101: 208-14.
46. Li J, Lockerbie O, de Korte D, et al., Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45: 920-6.
47. Mastroianni MA, Llohn AH, Akkök CA, et al., Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Transfus Apher Sci 2013; 49: 285-90.
48. Castrillo A, Cardoso M, Rouse L,. Treatment of buffy coat platelets in platelet additive solution with the Mirasol pathogen reduction technology system. Transfus Med Hemother 2013; 40: 44-8.
49. Cookson P, Thomas S, Marschner S, et al., In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 2012; 52: 983-94.
50. Galan AM, Lozano M, Molina P, et al., Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51: 808-15.
51. Reikvam H, Marschner S, Apelseth TO, et al., The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8: 186-92.
52. Ostrowski SR, Bochsen L, Salado-Jimena JA, et al., In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50: 2210-9.
53. Picker SM, Steisel A, Gathof BS,. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008; 48: 1685-92.
54. Picker SM, Tauszig ME, Gathof BS,. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012; 52: 510-6.
55. Janetzko K, Hinz K, Marschner S, et al., Evaluation of different preparation procedures of pathogen reduction technology(Mirasol)-treated platelets collected by plateletpheresis. Transfus Med Hemother 2009; 36: 309-15.
56. Zeddies S, De Cuyper IM, van der Meer PF, et al., Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54: 2292-300.
57. Prudent M, Sonego G, Abonnenc M, et al., LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets. J Am Soc Mass Spectrom 2014; 25: 651-61.
58. Prudent M, D'Alessandro A, Cazenave JP, et al., Proteome changes in platelets after pathogen inactivation-an interlaboratory consensus. Transfus Med Rev 2014; 28: 72-83.
59. Marrocco C, D'Alessandro A, Girelli G, et al., Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013; 53: 1808-20.
60. Prudent M, Crettaz D, Delobel J, et al., Proteomic analysis of INTERCEPT-treated platelets. J Proteomics 2012; 76SpecNo.: 316-28.
61. Schubert P, Culibrk B, Coupland D, et al., Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
62. Thiele T, Iuga C, Janetzky S, et al., Early storage lesions in apheresis platelets are induced by the activation of the integrin alphaIIbbeta(3) and focal adhesion signaling pathways. J Proteomics 2012; 76SpecNo.: 297-315.
63. Thiele T, Sablewski A, Iuga C, et al., Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation-a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012; 10: s63-70.
64. Kahn RA, Duffy BF, Rodey GG,. Ultraviolet irradiation of platelet concentrate abrogates lymphocyte activation without affecting platelet function in vitro. Transfusion 1985; 25: 547-50.
65. Pamphilon DH, Corbin SA, Saunders J, et al., Applications of ultraviolet light in the preparation of platelet concentrates. Transfusion 1989; 29: 379-83.
66. Capon SM, Sacher RA, Deeg HJ,. Effective ultraviolet irradiation of platelet concentrates in teflon bags. Transfusion 1990; 30: 678-81.
67. Andreu G, Boccaccio C, Lecrubier C, et al., Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice. Transfusion 1990; 30: 401-6.
68. Mohr H, Redecker-Klein A,. Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang 2003; 84: 96-104.
69. Gelderman MP, Chi X, Zhi L, et al., Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. Transfusion 2011; 51: 2343-57.
70. Chi X, Zhi L, Vostal JG,. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model. Transfusion 2014; 54: 74-85.
71. Verhaar R, Dekkers DW, De Cuyper IM, et al., UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112: 4935-9.
72. Hardwick CC, Herivel TR, Hernandez SC, et al., Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. Photochem Photobiol 2004; 80: 609-15.
73. Holme S, Moroff G, Murphy S,. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998; 38: 31-40.
74. Kilkson H, Holme S, Murphy S,. Platelet metabolism during storage of platelet concentrates at 22 degrees C. Blood 1984; 64: 406-14.
75. Ringwald J, Zimmermann R, Eckstein R,. The new generation of platelet additive solution for storage at 22 degrees C: development and current experience. Transfus Med Rev 2006; 20: 158-64.
76. Li J, Goodrich L, Hansen E, et al., Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage. Transfusion 2005; 45: 1750-8.
77. Paglia G, Sigurjõnsson OE, Rolfsson O, et al., Comprehensive metabolomic study of platelets reveals the expression of discrete metabolic phenotypes during storage. Transfusion 2014; 54: 2911-23.
78. Schubert P, Coupland D, Culibrk B, et al., Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013; 53: 3164-73.
79. Flevaris P, Li Z, Zhang G, et al., Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 2009; 113: 893-901.
80. Picker SM, Steisel A, Gathof BS,. Evaluation of white blood cell- and platelet-derived cytokine accumulation in MIRASOL-PRT-treated platelets. Transfus Med Hemother 2009; 36: 114-20.
81. Lindemann S, Tolley ND, Dixon DA, et al., Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-90.
82. Apelseth TO, Hervig TA, Wentzel-Larsen T, et al., Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006; 46: 800-10.
83. Tauszig ME, Picker SM, Gathof BS,. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transfus Apher Sci 2012; 46: 33-7.
84. Picker SM, Schneider V, Oustianskaia L, et al., Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49: 2311-8.
85. van Marwijk Kooy M, Akkerman JW, van Asbeck S, et al., UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br J Haematol 1993; 83: 253-8.
86. Zhi L, Chi X, Gelderman MP, et al., Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model. Transfusion 2013; 53: 722-31.
87. Bakkour S, Chafets DM, Wen L, et al., Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. Vox Sang 2014; 107: 351-9.